Factors Influencing Inclusion in Digestive Cancer Clinical Trials

Status Completed

Clinical Trial Summary

Since the early 1990s, evidence-based medicine has played an increasingly important role in decision-making for the treatment of patients with cancer. The highest level of evidence is attributed to the results of randomized comparative studies, and the public health authorities require proof from randomized therapeutic trials before authorizing the use of new treatments. Patients included in therapeutic trials benefit either from the best current treatment (control group) or from a treatment supposed to present a better or similar efficacy, together with an extremely rigorous surveillance protocol. Inclusion in a randomized therapeutic trial represents the optimal therapeutic strategy.In order to optimize the fight against cancer, French public health policies have led to the progressive implementation of successive nationwide "Cancer Plans" since 2003. One of the objectives is to increase the proportion of patients included in clinical research trials. Thus, the fraction enrolled in France has progressively increased but remained low at around 8% in 2010. The current 2014-2019 plan aims to expand inclusion to 50,000 patients per year. In a context of socio-economic inequalities that concern resources, residence and access to services, identifying factors that determine inclusion in trials will in turn highlight the reasons for non-inclusion.

The aim of this study was to determine, at a population level, the influence of demographic characteristics and socio-economic status of patients with digestive cancer on inclusion in a clinical trial.

Between 2004 and 2010, 4632 patients were recorded by the Burgundy Digestive Cancer Registry. According to a balancing score, the 136 patients included in a clinical trial were matched with 272 patients who met the eligibility criteria for trials. Deprivation was measured by the ecological European deprivation index. A conditional multivariate logistic regression was performed.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02894775
Study type	Observational
Source	Centre Hospitalier Universitaire Dijon
Contact
Status	Completed
Phase	N/A
Start date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04899492` - Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery	N/A
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Terminated	`NCT04589884` - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Completed	`NCT02386397` - Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	Phase 1/Phase 2
Recruiting	`NCT05121038` - CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab	Phase 1/Phase 2
Recruiting	`NCT04715581` - Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty	N/A
Completed	`NCT04008056` - Impact of Patient Reported Outcomes for Pre-chemotherapy Medical Decision in Day Patients With Digestive Cancer
Recruiting	`NCT05628857` - A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor	Phase 2
Terminated	`NCT03294252` - Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers	Phase 1/Phase 2
Completed	`NCT02169908` - Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin	N/A
Completed	`NCT02797197` - Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy	N/A
Completed	`NCT04379232` - Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center
Recruiting	`NCT05961111` - A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors	Early Phase 1
Recruiting	`NCT03449264` - Development of Clinical and Biological Database	N/A
Recruiting	`NCT04268121` - Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas	Phase 2
Recruiting	`NCT03670199` - Improving the Quality of Life of Cancer Patients Through a Perioperative and Coordinated Nutrition and Physical Care Program.	N/A
Withdrawn	`NCT01763489` - ASSIST Tool and Surgical Randomized Controlled Trial Applicability	N/A
Recruiting	`NCT04530890` - Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer	N/A
Recruiting	`NCT05867966` - Psychoneurological Symptom Cluster in Oncology	N/A
Not yet recruiting	`NCT04709055` - Complex Peri-operative Intervention in Older Patients With Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Factors Influencing Inclusion in Digestive Cancer Clinical Trials — INDICT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms